Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:IBIOOTCMKTS:NVLNFNASDAQ:PULMOTCMKTS:RZLTD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$1.77+2.9%$0.00$1.02▼$22.80$6.17M-3.513.00 million shs60,182 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsPULMPulmatrix$2.04-1.9%$1.87$1.55▼$3.14$7.45M0.9217,328 shs6,762 shsRZLTDRezolute$2.60-10.0%$2.20$16.00▼$24.05$21.89M4.634,788 shs455,095 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio-8.99%-2.82%+36.51%+171,999,900.00%+171,999,900.00%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%PULMPulmatrix-0.48%+6.67%+23.03%+15.56%-24.09%RZLTDRezolute+1.05%-10.80%+52.91%+158.04%+40.98%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBIOiBioN/AN/AN/AN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix1.4544 of 5 stars3.53.00.00.01.40.00.6RZLTDRezoluteN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBIOiBioN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/APULMPulmatrix3.00Buy$10.00390.20% UpsideRZLTDRezoluteN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBIOiBio$50K123.33N/AN/A$15.15 per share0.12NVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15PULMPulmatrix$7.30M1.02N/AN/A$4.93 per share0.41RZLTDRezoluteN/AN/AN/AN/A$1.24 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/ANVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/APULMPulmatrix-$14.12M-$3.86N/A∞N/A-193.49%-63.94%-40.88%5/10/2024 (Estimated)RZLTDRezolute-$20.33MN/A0.00∞N/AN/A-153.46%-111.71%N/ALatest IBIO, RZLTD, NVLNF, and PULM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PULMPulmatrixN/A-$0.57-$0.57-$0.57N/A$2.20 million2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBIOiBioN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ARZLTDRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBIOiBio0.040.910.91NVLNFNovelion TherapeuticsN/AN/AN/APULMPulmatrixN/A5.335.33RZLTDRezoluteN/A3.263.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBIOiBio7.90%NVLNFNovelion Therapeutics48.64%PULMPulmatrix11.84%RZLTDRezoluteN/AInsider OwnershipCompanyInsider OwnershipIBIOiBio1.12%NVLNFNovelion Therapeutics3.60%PULMPulmatrix3.61%RZLTDRezolute4.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIBIOiBio263.48 million3.45 millionN/ANVLNFNovelion Therapeutics10919.62 millionN/ANot OptionablePULMPulmatrix223.65 million3.52 millionNot OptionableRZLTDRezolute238.42 millionN/ANot OptionableIBIO, RZLTD, NVLNF, and PULM HeadlinesSourceHeadlineAmerica/Resolute Time zone • Current Time in Resoluteprokerala.com - November 11 at 10:42 PMRezolute (RZLT) Earnings Dates & Reportsinvesting.com - November 9 at 8:09 AMXilio Development Inc (XLO)investing.com - September 3 at 8:34 PMSystems Ltd.forbes.com - August 9 at 6:47 PMStonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Diseasebenzinga.com - June 1 at 3:38 PMAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Jazz Pharmaceuticals (JAZZ)markets.businessinsider.com - May 15 at 7:36 AMRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progressfinanznachrichten.de - May 12 at 4:09 AMRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progressfinance.yahoo.com - May 11 at 6:07 PMGreat news for Rezolute, Inc. (NASDAQ:RZLT): Insiders acquired stock in large numbers last yearfinance.yahoo.com - April 25 at 9:16 AMRezolute (RZLT) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - March 28 at 8:47 AMRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progressfinanznachrichten.de - February 12 at 7:31 AMRezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progressfinance.yahoo.com - February 10 at 6:54 PMXeris Biopharma Holdings Stock (NASDAQ:XERS), Quotes and News Summarybenzinga.com - February 7 at 7:20 AMAfter losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gainfinance.yahoo.com - February 2 at 11:06 AMAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Rezolute (RZLT)markets.businessinsider.com - November 10 at 1:53 AMRezolute to Present at the Jefferies London Healthcare Conferencetechnews.tmcnet.com - November 1 at 8:59 AMNew MarketBeat Followers Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsiBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Novelion TherapeuticsOTCMKTS:NVLNFNovelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.RezoluteOTCMKTS:RZLTDRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.